Mergen, Oxford Gene Technology Settle Patent Infringement Suit
Under the terms of the settlement, Mergen has obtained a license from OGT for its expression chips in the U.S., Europe and Japan. This license allows Mergen to manufacture and sell microarrays, the company said.
Financial terms of the settlement agreeement were not revealed.
“We believe that this license will give Mergen valuable freedom to operate and grow its expression profiling oligo microarray business...
To view the full article, register now.